
News|Videos|June 27, 2024
Conversations With Patients About Mild/Moderate Multiple Sclerosis
The expert panel examines early multiple sclerosis (MS) and patients with mild MS even in later stages of the disease, emphasizing crucial information to convey to patients throughout their journey; faculty also explore cases where disease-modifying therapies (DMTs) may not be utilized.
Advertisement
Episodes in this series

- What is important for physicians to share with different types of patients and with patients at different junctures of their MS journey?
- Are there any patients with mild disease who won’t be treated with DMTs?
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Cladribine Tablets Show Ability to Improve or Stabilize Cognitive Function in Patients With Relapsing Multiple Sclerosis
2
Myelin Protective Small Molecule Lucid-MS Shows Promising Early-Stage Data in Healthy Volunteers
3
Using Human iPSC Models to Dissect PIRA Mechanisms in Progressive Multiple Sclerosis: Valentina Fossati, PhD
4
Phase 3b RESHAPE Study Evaluates Risk–Benefit of Switching From Ocrelizumab to BTK Inhibitor Remibrutinib
5






